Danmarks Nationalbank
22.1.2025 16:01:01 CET | Globenewswire | Press release
OPENING OF NEW 10-YEAR BENCHMARK BOND ON 5 FEBRUARY 2025
OPENING OF NEW 10-YEAR BENCHMARK BOND ON 5 FEBRUARY 2025
On 5 February 2025, the Kingdom of Denmark will issue a new DGB 2.25 per cent 2035 (ISIN: DK0009924961) via auction. Coupons will be paid annually on 15 November and maturity will be on 15 November 2035. The new bond will replace DGB 2.25 per cent 2033 as key on-the-run issue. After this the central government can conduct buy-backs in DGB 2.25 per cent 2033.
The sale will commence via MTS Denmark's auction system with primary dealers as counterparts. The opening is contingent on stable market conditions. At the auction, the total sale will not exceed DKK 6 billion at nominal value.
As from 8:00 a.m. (CET) on the opening day, bids can be submitted until 10:15 a.m. Subsequently, a cut-off price will be fixed as quickly as possible and within 10 minutes at the latest. Bids at the cut-off price or above will be accommodated at the cut-off price. A pro-rata allocation of bids at the cut-off price may be applied.
Terms of borrowing can be viewed on www.governmentdebt.dk under Terms of borrowing.
SECURITIES LENDING
DGB 2.25 per cent 2035 will be included in the central government's securities lending facility from 5 February 2025.
FURTHER INFORMATION
For further information please contact the Danish debt management office at governmentdebt@nationalbanken.dk.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom